Metagenomi Therapeutics (MGX) Net Cash Flow (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Net Cash Flow data on file, last reported at -$17.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$17.2 million, down 1051.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.7 million (up 93.53% YoY), and the FY2025 annual result was $14.3 million, up 112.61% from the prior year.
• Net Cash Flow fell to -$17.2 million in Q1 2026 per MGX's latest filing, from $8.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $50.2 million in Q3 2023 and troughed at -$88.8 million in Q1 2023.
• A 4-year average of -$12.4 million and a median of -$2.3 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow surged 291.98% in 2025, then tumbled 1051.69% in 2026.
• A 4-year view of Net Cash Flow shows it stood at $38.7 million in 2023, then slumped by 94.14% to $2.3 million in 2024, then surged by 291.98% to $8.9 million in 2025, then slumped by 293.57% to -$17.2 million in 2026.
• Business Quant data shows MGX's Net Cash Flow at -$17.2 million in Q1 2026, $8.9 million in Q4 2025, and $5.9 million in Q3 2025.